Conditions: Other Skin
Interventions: Biological: Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR; Drug: Avelumab; Biological: Pembrolizumab; Biological: Interferon Gamma-1b
Sponsors: Fred Hutchinson Cancer Center; National Cancer Institute (NCI); Affini-T Therapeutics, Inc.
Active, not recruiting